Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study

View Full Paper
Ask AI
Bookmark
Share

Authors

YMYong MunAcentech (United States)

Discussion

Loading...

Member takes

Implication

Phase II study demonstrates potential of mosunetuzumab to improve safety and outcomes in elderly DLBCL patients, suggesting a viable alternative to chemotherapy.

Key Points

  • This study aimed to evaluate the efficacy and safety of subcutaneous mosunetuzumab in elderly or unfit patients with DLBCL.
  • Open-label, multicenter, Phase II, basket study
  • Patients aged ≥80 or aged 65–79 ineligible for chemoimmunotherapy
  • Step-up dosing scheme for mosunetuzumab administered subcutaneously
  • Primary endpoint focused on progression-free survival at 24 months
  • PFS rate at 12 months was 68.8%
  • ORR was 73.5% and CR was 59.2%
  • Median number of cycles received was 14
  • Median age of participants was 82.5 years
  • Adverse events were primarily mild to moderate, with injection site reactions being the most common

Cite This Study

Yong Mun (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236cfd5https://doi.org/10.1182/blood-2025-62
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Fixed-duration subcutaneous (SC) mosunetuzumab (Mosun) in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Interim analysis and patient-reported outcomes (PROs) from the phase 2 MorningSun study.2026
  2. 2Fixed-duration subcutaneous mosunetuzumab demonstrates sustained clinically meaningful outcomes in patients with previously untreated, low-tumor burden follicular lymphoma2025 · 1 citations
  3. 3Fixed-duration subcutaneous (SC) mosunetuzumab, with maintenance therapy, in patients (pts) with previously untreated high-tumor burden follicular lymphoma (HTB FL): Longer follow-up and exploratory circulating tumor (ct)DNA analysis of the Phase II MorningSun study2025 · 2 citations
  4. 4Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study2025 · 1 citations
  5. 5Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study2025 · 3 citations